Distinguished in Hepatitis

Bo Feng

Beijing Key Laboratory Of Hepatitis C And Immunotherapy For Liver Diseases, 
Beijing, CN 
Distinguished in Hepatitis
Beijing Key Laboratory Of Hepatitis C And Immunotherapy For Liver Diseases, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Bo Feng practices in Beijing, China. Mr. Feng is rated as a Distinguished expert by MediFind in the treatment of Hepatitis. His top areas of expertise are Hepatitis C, Hepatitis, Hepatitis B, and Cirrhosis.

His clinical research consists of co-authoring 81 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 56 articles and participated in 4 clinical trials in the study of Hepatitis.

Gender
Male

Locations

Beijing Key Laboratory Of Hepatitis C And Immunotherapy For Liver Diseases, Beijing, 100044, China
Other Locations
No.11 Xizhimen South Street, Xizhimen, 100044, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)
Enrollment Status: Active_not_recruiting
Publish Date: April 28, 2021
Intervention Type: Drug
Study Drug: Entecavir
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Optimized Treatment and Regression of HBV-induced Liver Fibrosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Enrollment Status: Completed
Publish Date: July 27, 2018
Intervention Type: Drug
Study Phase: Phase 4
View 3 Less Clinical Trials

81 Total Publications

STING knockdown blocks disease progression and inflammation in mice with alcoholic liver disease by relieving pyroptosis via suppressing NLRP3.
STING knockdown blocks disease progression and inflammation in mice with alcoholic liver disease by relieving pyroptosis via suppressing NLRP3.
Journal: International immunopharmacology
Published: July 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Feng's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile